Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Tax Provisions (2022 - 2024)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Tax Provisions data on record, last reported at -$205000.0 in Q4 2024.

  • For Q4 2024, Tax Provisions fell 51.85% year-over-year to -$205000.0; the TTM value through Sep 2025 reached -$205000.0, down 183.0%, while the annual FY2024 figure was $177000.0, 129.45% up from the prior year.
  • Tax Provisions reached -$205000.0 in Q4 2024 per ZNTL's latest filing, down from -$27000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $266000.0 in Q2 2024 and bottomed at -$605000.0 in Q2 2023.
  • Average Tax Provisions over 3 years is -$74416.7, with a median of -$5000.0 recorded in 2022.
  • The widest YoY moves for Tax Provisions: up 227.27% in 2023, down 3658.82% in 2023.
  • A 3-year view of Tax Provisions shows it stood at -$360000.0 in 2022, then surged by 62.5% to -$135000.0 in 2023, then plummeted by 51.85% to -$205000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$205000.0 in Q4 2024, -$27000.0 in Q3 2024, and $266000.0 in Q2 2024.